CCCR-NK92 cells

Phase 1Biologic

HHenan Medical University

CCCR-NK92 cells is one of 51 biologic programs targeting Non-Small Cell Lung Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CarcinomaActive, not recruiting

Non-Small Cell Lung CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

80 competitors in Non-Small Cell Lung Carcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

6 2

Keytruda

Merck & Co.

Phase 3

5 3

Abraxane

Bristol-Myers Squibb

Phase 3

2 4

Dostarlimab

Incyte

Phase 3

1 5

Alecensa

Roche

Phase 3

1 6

Plavix

Sanofi

Phase 3

1 7

Paraplatin

AAvyxa

Phase 3

7 8

DATROWAY

Cabometyx

Alimta

EEagle Vision Pharmaceutical Corp.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Carcinoma1 trial

CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma

Completed·HHenan Medical University·Phase 1·NCT03656705·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CCCR-NK92 cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CCCR-NK92 cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CCCR-NK92 cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: HHenan Medical University

CCCR-NK92 cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News